{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T09:27:22Z","timestamp":1771493242402,"version":"3.50.1"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,4,19]],"date-time":"2011-04-19T00:00:00Z","timestamp":1303171200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1186\/1745-6215-12-99","type":"journal-article","created":{"date-parts":[[2011,4,23]],"date-time":"2011-04-23T16:34:50Z","timestamp":1303576490000},"source":"Crossref","is-referenced-by-count":8,"title":["A pseudo-randomised clinical trial of in situ gels of fluconazole for the treatment of oropharngeal candidiasis"],"prefix":"10.1186","volume":"12","author":[{"given":"Harish M","family":"Nairy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Narayana R","family":"Charyulu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veena A","family":"Shetty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prabhu","family":"Prabhakara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,4,19]]},"reference":[{"key":"631_CR1","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/S0149-2918(97)80131-2","volume":"19","author":"PA Murray","year":"1997","unstructured":"Murray PA, Koletar SL, Jane Wu IM, Moskovitz BL: Itraconazole Oral Solution Versus Clotrimazole Troches for the Treatment of Oropharyngeal Candidiasis in Immunocompromised Patients. Clin Ther. 1997, 19: 471-80. 10.1016\/S0149-2918(97)80131-2.","journal-title":"Clin Ther"},{"key":"631_CR2","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S0732-8893(02)00432-7","volume":"44","author":"PF-TC Munoz","year":"2002","unstructured":"Munoz PF-TC, Alcala L, Rodriguez-Creixems M, Pelaez T, Bouza E: Frequency and clinical significance of bloodstream infections caused by C. albicans strains with reduced susceptibility to fluconazole. Diagn Microbiol Infect. 2002, 44: 163-7. 10.1016\/S0732-8893(02)00432-7.","journal-title":"Diagn Microbiol Infect"},{"key":"631_CR3","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1034\/j.1399-302x.2000.150406.x","volume":"15","author":"TM Waltimo","year":"2000","unstructured":"Waltimo TM, Orstavik D, Meurman JH, Samaranayake LP, Haapasalo MP: In vitro susceptibility of Candida albicans isolates from apical and marginal periodontitis to common antifungal agents. Oral Microbiol Immunol. 2000, 15: 245-248. 10.1034\/j.1399-302x.2000.150406.x.","journal-title":"Oral Microbiol Immunol"},{"key":"631_CR4","first-page":"698","volume-title":"Merck Index","author":"B Susan","year":"1996","unstructured":"Susan B: Merck Index. 1996, Whitehouse Station, NJ: Merck & Co, Inc, 698-12","edition":"12"},{"key":"631_CR5","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1086\/380796","volume":"38","author":"PG Pappas","year":"2004","unstructured":"Pappas PG, Rex JH, Sobel JD: Guidelines for treatment of candidiasis. Clin Infect Dis. 2004, 38: 161-89. 10.1086\/380796.","journal-title":"Clin Infect Dis"},{"key":"631_CR6","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1002\/cncr.23152","volume":"112","author":"RJ Bensadoun","year":"2008","unstructured":"Bensadoun RJ, Daoud J, Gueddari ElB, Bastit L, Gourmet R, Rosikon A, Allavena C, Ceruse P, Calais G, Attali P: Comparison of the efficacy and safety of miconazole 50-mg mucoadhesive buccal tablets with miconazole 500-mg gel in the treatment of oropharyngeal candidiasis: a prospective, randomized, single-blind, multicenter, comparative, phase III trial in patients treated with radiotherapy for head and neck cancer. Cancer. 2008, 112: 204-11. 10.1002\/cncr.23152.","journal-title":"Cancer"},{"key":"631_CR7","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1248\/yakushi.129.569","volume":"129","author":"NR Charyulu","year":"2009","unstructured":"Charyulu NR, Harish NM, Gulzar MA, Prabhu P, Singh AK, Subrahmanyam EVS: Formulation and In Vitro Evaluation of In Situ Gels Containing Secnidazole for Vaginitis. Yakugaku Zadussi. 2009, 129: 569-574. 10.1248\/yakushi.129.569.","journal-title":"Yakugaku Zadussi"},{"key":"631_CR8","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S0378-5173(02)00054-6","volume":"239","author":"BY Choi","year":"2002","unstructured":"Choi BY, Park HJ, Hwang SJ, Park JB: Biological interactions between divalent cation and polysaccharides. Int J Pharm. 2002, 239: 81-91. 10.1016\/S0378-5173(02)00054-6.","journal-title":"Int J Pharm"},{"key":"631_CR9","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S0378-5173(98)00351-2","volume":"178","author":"F Kedzierewicz","year":"1999","unstructured":"Kedzierewicz F, Lombry C, Rios R, Hoffman M, Maincent P: Effect of the formulation on the in vitro release of propranolol from gellan beads. Int J Pharm. 1999, 178: 129-136. 10.1016\/S0378-5173(98)00351-2.","journal-title":"Int J Pharm"},{"key":"631_CR10","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1128\/AAC.34.11.2267","volume":"34","author":"SL Koletar","year":"1990","unstructured":"Koletar SL, Russell JA, Fass RJ, Plouffe JF: Comparison of oral fluconazole and clotrimazole troches as treatment for oral candidiasis in patients with human immunodeficiency virus. Antimicrob Agents Chemothe. 1990, 34: 2267-2268.","journal-title":"Antimicrob Agents Chemothe"},{"issue":"3","key":"631_CR11","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/S0149-2918(97)80131-2","volume":"19","author":"AM Patricia","year":"1997","unstructured":"Patricia AM, Susan LK, Irma M, Jane Wu, Bruce LM: Itraconazole Oral Solution Versus Clotrimazole Troches for the Treatment of Oropharyngeal Candidiasis in Immunocompromised Patients. Clin Ther. 1997, 19 (3): 471-480. 10.1016\/S0149-2918(97)80131-2.","journal-title":"Clin Ther"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1745-6215-12-99\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1745-6215-12-99.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1745-6215-12-99","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1745-6215-12-99.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,22]],"date-time":"2019-01-22T15:01:33Z","timestamp":1548169293000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/1745-6215-12-99"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4,19]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["631"],"URL":"https:\/\/doi.org\/10.1186\/1745-6215-12-99","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4,19]]},"article-number":"99"}}